双歧杆菌三联活菌散/胶囊应用于消化系统疾病的中国专家共识(2021版)  

Chinese expert consensus on application of live combined Bifidobacterium,Lactobacillus and Enterococcus powder/capsule in digestive system diseases(version 2021)

作　　者：中华消化杂志编辑委员会 房静远[2] 杨云生[3] 谢渭芬 Editorial Board of Chinese Journal of Digestion;Fang Jingyuan;Yang Yunsheng;Xie Weifen(不详;Department of Gastroenterology,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200001,China;Department of Gastroenterology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China;Department of Gastroenterology,the Second Affiliated Hospital(Shanghai Changzheng Hospital)of Naval Medical University,Shanghai 200003,China)

机构地区：[1]不详 [2]上海交通大学医学院附属仁济医院消化内科,上海200001 [3]解放军总医院第一医学中心消化科,北京100853 [4]海军军医大学第二附属医院(上海长征医院)消化内科,上海200003

出　　处：《中华消化杂志》2022年第4期224-239,共16页Chinese Journal of Digestion

摘　　要：随着消化道微生态的研究进展,发现肠道菌群与消化系统疾病存在密切关联。肠道菌群紊乱参与了感染性、炎症性或功能性胃肠道疾病和肝胆系统疾病的病理变化过程。益生菌可通过多种调节肠道微生态环境的机制改善患者症状,发挥临床疗效。因此,近年来益生菌制剂被广泛用于消化系统疾病领域。双歧杆菌三联活菌散/胶囊是国内临床常用的益生菌制剂,其包含长双歧杆菌、嗜酸乳杆菌和粪肠球菌3种菌株,可联合不同菌种的特性和益生功效发挥平衡肠道菌群、调节免疫和修复肠道屏障等作用。该制剂已在临床实践中被证明具有良好的安全性和有效性,但其对消化系统疾病的治疗作用仍存在一定不确定性,缺乏临床指导与规范。鉴于国内尚无该制剂相关专家共识,现基于目前国内外临床研究证据和专家经验,形成双歧杆菌三联活菌散/胶囊在成人和儿童消化系统疾病中的临床应用和相关问题的共识,以期为其临床合理用药提供参考。For the advances of gastrointestinal microecology,the relationship between gut microbiome and digestive system diseases has been found.Disturbance of gut microbiota,is proven to be involved in the pathological changes of infectious,inflammatory or functional gastrointestinal diseases and hepatobiliary diseases.On the other side,probiotics have been demonstrated to improve symptoms and exert clinical efficacy through a variety of mechanisms to regulate gastrointestinal micro-ecological environment.Therefore,probiotics have been widely used in maintaining gastrointestinal health in recent years.Live combined Bifidobacterium,Lactobacillus and Enterococcus powder/capsule is a probiotic product commonly used in clinical practice in China.It contains three strains of Bifidobacterium longum,Lactobacillus acidophilus and Enterococcus faecalis,which can play a synergistic role in balancing microbiome,regulating immunity and repairing gut barrier with different strain characteristics and probiotic effects.Although this probiotic product has been proved to be safe and effective in clinical practice for many years,but there is still some uncertainty in the treatment of digestive system diseases and lack of reference standard to guide clinical practice,and also no relevant expert consensus on this product in China.Based on the latest available evidence from literature review and clinical experience,a consensus on the clinical application and related problems of live combined Bifidobacterium,Lactobacillus and Enterococcus in different adult and child digestive system diseases has been formed,in order to provide reference for its clinical rational drug use.

关 键 词：双歧杆菌三联活菌 益生菌 胃肠道微生物组 消化系统疾病 

分 类 号：R57[医药卫生—消化系统]